Although a variety of methods have become available for the determination of high-density lipoprotein (HDL) subfractions in plasma, a review of published data from nine studies of coronary disease outcomes and 10 investigations of coronary artery disease severity do not suggest that measurement of HDL2-cholesterol (C) and HDL3-C offer any advantage in the prediction of coronary disease over the determination of total HDL-C alone. Apolipoprotein E is typically present in plasma as one of six isoforms, the six being encoded by three common alleles, #{128}2, #{128}3, arid #{128}4. The #{128}3 allele is the most common, the #{128}4 allele has been reported to be associated with higher choles- (Fig. 1) Several studies showed an association be-
HDL subfractions by ultracentrifugation, and showed that both HDL2 and HDL3 were highly associated with CHD and the severity of atherosclerosis (6, 7).
Similar studies over the years usually replicated these results, but not in all instances
(1). Although the data showed that both HDL2 and HDL3 were associated with CHD, the results did not suggest that these measurements significantly improved prediction of CHD more than determination of HDL-C alone. The isoforms of apolipoprotein E (apoE) have interested lipid researchers for the past two decades, and three alleles (#{128}2, #{128}3, and #{128}4) are responsible for the six The results parallel those for the CHD studies (1). Similar degrees of association with the severity of CAD were typically observed for HDL-C, HDL2-C, and HDL3-C, although the associations were not always f""" Cumming(1984) Lenzen (1986) Eto ( mean concentrations of H1)L-C was observed, but both #{128}2 and #{128}4 appeared to be associated with a tendency toward higher triglycerides (9). Investigators have subsequently studied coronary risk and atherosclerosis in association with the apoE alleles (8, 43). The apoE isoform data were abstracted from published reports of several coronary and angiographic studies to estimate the #{128}2 and #{128}4 allele frequencies among cases and non-cases.
The apoE allele frequencies allowed calculation of the relative odds for CHD according to the #{128}4 and #{128}2 alleles (45-49), as summarized in Fig. 2 . Both studies with CHD endpoints (8, [50] [51] [52] [53] [54] and those for CAD (44, (55) (56) (57) are shown. The #{128}4 allele was associated with an increased odds for CHD in five of six CHD studies (two were statistically significant) and in three of four angiographic studies (one was statistically significant).
Similarly, the #{128}2 allele was associated with CHD in three of six CHD reports (two were statistically significant) and in two of four angiographic studies (none statistically significant).
Although a formal metaanalysis was not performed (45, 46), the data suggest that the #{128}4 allele was mildly associated with increased risk of CAD and CHD, and that the #{128}2 allele had less of an impact.
The apoE alleles appear to increase the relative odds for CHI) and CAD largely by way of their association with abnormal lipids. The #{128}4 allele was first described as positively associated with LDL-C, but associations with other lipids should also be considered; e.g., Dallongeville et al. (9) have described higher triglycerides associated with both the #{128}2 and the #{128}4 alleles. The latter finding would also help to explain why the presence of the #{128}2 allele is not associated with cardioprotection, even though the LDL-C concentrations are lower than for the #{128}3 or #{128}4 alleles. 
